|Place of Origin:||China|
|Model Number:||0.5g; 0.75g; 1.0g; 1.5g; 2.0g|
|Minimum Order Quantity:||100000 vials|
|Packaging Details:||50 vials/box|
|Supply Ability:||500, 000 vials per day|
|Product:||Ceftazidime For Injection||Specification:||0.5g; 0.75g; 1.0g; 1.5g; 2.0g|
Ceftazidime Antibiotic Sodium / Ceftazidime For Injection 0.5G - 2.0G
Product : Ceftazidime for Injection
Specification : 0.5g; 0.75g; 1.0g; 1.5g; 2.0g
Standard : BP, USP
Semisynthetic, broad-spectrum antibacterial derived from cephaloridine and used especially for Pseudomonas and other gram-negative infections in debilitated patients.
For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis, primarily penicillin binding protein 3 (PBP3). A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins. Ceftazidime has activity against the gram-negative organisms Pseudomonas and Enterobacteriaceae. Its activity against Pseudomonas is a distinguishing feature of ceftazidime among the cephalosporins.
Mechanism of action
The bactericidal activity of ceftazidime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).